cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2012-6-85-90cardiovascular-2038Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESСтатины и сахарный диабет: риск и пользаStatins and diabetes mellitus: risks and benefitsДрапкинаО. М.DrapkinaO. M.doctorok@land.ruКорнееваО. Н.KorneevaO. N.doctorok@land.ruШептулинаА. Ф.SheptulinaA. F.doctorok@land.ruПервый Московский государственный медицинский университет имени И. М. Сеченова, МоскваРоссияI. M. Sechenov First Moscow State Medical University, MoscowRussian Federation2012201220121168590Copyright © Драпкина О.М., Корнеева О.Н., Шептулина А.Ф., 20122012Драпкина О.М., Корнеева О.Н., Шептулина А.Ф.Drapkina O.M., Korneeva O.N., Sheptulina A.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2038

Пациенты с сахарным диабетом (СД) составляют группу высокого риска сердечно-сосудистых осложнений (ССО). В настоящее время большинство клиницистов придерживаются тактики, направленной на интенсивное снижение уровня холестерина липопротеинов низкой плотности и артериального давления (АД) у пациентов с СД с целью профилактики сердечно-сосудистых заболеваний. Одним из классов препаратов, наиболее часто назначаемых больным СД, являются статины. В течение последних лет в литературе появляются сообщения об увеличении риска развития СД на фоне приема статинов, которые вновь обратили внимание исследователей и клиницистов на вопрос безопасности их назначения пациентам, относящимся к категории высокого риска ССО. Данный обзор посвещен проблеме развития СД на фоне терапии статинами.

Patients with diabetes mellitus (DM) are at a high risk of cardiovascular events (CVE). Currently, the predominant clinical strategy of the CVE prevention in DM patients is aggressive lowering of low-density lipoprotein cholesterol and blood pressure levels. In this clinical group, statins are among the most widely used pharmacological agents. Recent clinical evidence suggests that statin therapy could be associated with an increased risk of DM. Both clinicians and researchers need to reevaluate the issue of statin safety in the patients at a higher CVE risk. This review focuses on the problem of DM development in statin-treated patients.

статинысахарный диабетсердечно-сосудистые заболеванияβ-клетки поджелудочной железыstatinsdiabetes mellituscardiovascular diseasepancreatic β-cellsReferencesBaigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670–81.Uchechukwu K Sampsona, MacRae F. Lintona, Sergio Fazioa. Are statins diabetogenic? Curr Opin Cardiol 2011; 26(4): 342–7.Uchechukwu K Sampsona, MacRae F. Lintona, Sergio Fazioa. Are statins diabetogenic? Curr Opin Cardiol 2011; 26(4): 342–7.Jonas Rutishauser. Statins in clinical medicine. Swiss Med Wkly 2011.Jonas Rutishauser. Statins in clinical medicine. Swiss Med Wkly 2011.Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–78.Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–78.Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104(2): 109–24.Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104(2): 109–24.McCarron P, Greenwood R, Elwood P, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001; 115: 12–20.McCarron P, Greenwood R, Elwood P, et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 2001; 115: 12–20.American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care 2008; 31(Suppl 1): S12–54.American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care 2008; 31(Suppl 1): S12–54.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39.Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39.Justin W. Timbie, Rodney A. Hayward, Sandeep Vijan. Variation in the net benefit of aggressive cardiovascular risk factor control across the US diabetes population. Arch Intern Med 2010; 170(12): 1037–44.Justin W. Timbie, Rodney A. Hayward, Sandeep Vijan. Variation in the net benefit of aggressive cardiovascular risk factor control across the US diabetes population. Arch Intern Med 2010; 170(12): 1037–44.Swapnil N. Rajpathak, Dharam J. Kumbhani, Jill Crandall, et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care 2009; 32(10): 1924-9.Swapnil N. Rajpathak, Dharam J. Kumbhani, Jill Crandall, et al. Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care 2009; 32(10): 1924-9.Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital Heart J 2000; 1: 810–20.Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico). Ital Heart J 2000; 1: 810–20.Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007.Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30.Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149–58.Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet 2003; 361: 1149–58.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735–42.Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735–42.Waters DD. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. JACC 2011; 57: 1535-45.Waters DD. Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Results From 3 Large Randomized Clinical Trials. JACC 2011; 57: 1535-45.Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 57: 495–9.Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 57: 495–9.Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010; 87: 98–107.Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in nondiabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010; 87: 98–107.Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21: 178–85.Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21: 178–85.Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005; 12: 111–9.Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005; 12: 111–9.Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881–92.Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681–4.Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681–4.Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 357–61.Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001; 507: 357–61.Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007; 56: 2328–38.Hao M, Head WS, Gunawardana SC, et al. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007; 56: 2328–38.Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. JACC 2007; 49: 2129–38.Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. JACC 2007; 49: 2129–38.Sabatine MS, Wiviott SD, Morrow DA, et al. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract). Circulation 2004; 110: S834.Sabatine MS, Wiviott SD, Morrow DA, et al. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract). Circulation 2004; 110: S834.Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483–90.Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009; 204: 483–90.Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006; 13: 329–35.Ishikawa M, Okajima F, Inoue N, et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006; 13: 329–35.Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325–31.Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325–31.Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009; 106: 13998–4003.Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009; 106: 13998–4003.Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356–70.Ehses JA, Perren A, Eppler E, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56: 2356–70.Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)- 1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and auto-stimulation. J Clin Endocrinol Metab 2008; 93: 4065–74.Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)- 1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and auto-stimulation. J Clin Endocrinol Metab 2008; 93: 4065–74.Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517–26.Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517–26.Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007; 50: 1304–14.Abderrahmani A, Niederhauser G, Favre D, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007; 50: 1304–14.Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002; 143: 3449–53.Cnop M, Hannaert JC, Grupping AY, Pipeleers DG. Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002; 143: 3449–53.Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278: 18368–75.Roehrich ME, Mooser V, Lenain V, et al. Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003; 278: 18368–75.Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046–51.Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046–51.Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 2005; 68(Suppl.2): S3–14.Leiter LA. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 2005; 68(Suppl.2): S3–14.Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1–11.Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1–11.Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004; 137: 675–82.Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004; 137: 675–82.Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112: 93–102.Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112: 93–102.

The authors declare that there are no conflicts of interest present.